Research graph
References from Predictors of relapse following transition to ofatumumab in relapsing-remitting multiple sclerosis. Local targets link to admitted publications; unresolved targets remain external evidence.
OLIKOS Study: 6-month interim efficacy and safety in patients with relapsing multiple sclerosis who switched to subcutaneous Ofatumumab from intravenous anti- CD20 therapies
10.1212/wnl.0000000000204967 · 2024 · External reference
Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice
10.1080/17582024.2025.2452150 · 2025 · External reference
Fingolimod Rebound: a review of the clinical experience and management considerations
10.1007/s40120-019-00160-9 · 2019 · External reference
Efficacy of early Ofatumumab versus late-switch from Teriflunomide: subgroup analysis of the ALITHIOS open-label extension study by prior disease modifying therapy exposure and age
2022 · External reference
Efficacy of ofatumumab in treatment-naive, first-switch and late-switch patients: insights from the Alithios openlabelextension study
2022 · External reference
Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic
10.1016/j.msard.2023.104881 · 2023 · External reference
Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic
10.3389/fimmu.2023.1004795 · 2023 · External reference
Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension
10.1177/13524585231195346 · 2023 · External reference
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
10.1016/j.msard.2024.105888 · 2024 · External reference
Infection risks among patients with multiple sclerosis treated with Fingolimod, Natalizumab, Rituximab, and injectable therapies
10.1001/jamaneurol.2019.3365 · 2020 · External reference
Ofatumumab in different RMS patient populations in everyday clinical practice in Germany
10.1212/wnl.0000000000206124 · 2024 · External reference
Impact of discontinuing disease-modifying therapies on health care utilization among midlife patients with multiple sclerosis in the United States
2024 · External reference
Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis
10.1212/wnl.0000000000201029 · 2022 · External reference
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy
10.1177/13524585211005657 · 2022 · External reference
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study
10.1007/s00415-024-12360-x · 2024 · External reference
Prediction of multiple sclerosis outcomes when switching to ocrelizumab
10.1177/13524585211049986 · 2022 · External reference
